Metastatic Non-squamous Non Small Cell Lung Cancer (DBCOND0044105)

Identifiers

Synonyms

Metastatic Non-Squamous Non-Small Cell Lung Cancer / Metastatic nonsquamous non-small cell lung cancer

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Atezolizumab	A monoclonal antibody used to treat advanced or metastatic urothelial carcinoma with disease progression during or up to 12 months after platinum-containing chemotherapy.	Programmed cell death 1 ligand 1target Programmed cell death protein 1target
Bevacizumab	A monoclonal anti-vascular endothelial growth factor antibody used in combination with antineoplastic agents for the treatment of many types of cancer.	Vascular endothelial growth factor A, long formtarget Complement C1q subcomponent subunit Atarget Complement C1q subcomponent subunit Btarget Complement C1q subcomponent subunit Ctarget Low affinity immunoglobulin gamma Fc region receptor III-Atarget Low affinity immunoglobulin gamma Fc region receptor II-atarget Low affinity immunoglobulin gamma Fc region receptor II-btarget Low affinity immunoglobulin gamma Fc region receptor II-ctarget High affinity immunoglobulin gamma Fc receptor Itarget
Pemetrexed	A folate analog used to treat mesothelioma and non-small cell lung cancer.	Thymidylate synthasetarget Dihydrofolate reductasetarget Trifunctional purine biosynthetic protein adenosine-3target Deoxycytidine kinaseenzyme Bifunctional purine biosynthesis protein ATICtarget Equilibrative nucleoside transporter 1enzyme Organic anion transporter 3transporter Reduced folate transportertransporter Proton-coupled folate transportertransporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter ATP-binding cassette sub-family C member 5transporter Solute carrier family 22 member 6transporter Albumincarrier Solute carrier family 22 member 11transporter Thymidylate synthasetarget

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT03906071	Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer	Docetaxel Nivolumab Sitravatinib	treatment	3	active_not_recruiting
NCT06463665	Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer	Atezolizumab Cemiplimab Cisplatin Docetaxel Durvalumab Nivolumab Olvimulogene nanivacirepvec Paclitaxel Pembrolizumab Pemetrexed Platinum	treatment	2	recruiting
NCT00942825	Triplet Combination First Line Treatment in Non Small Cell Lung Cancer (NSCLC)	CBP-501 Cisplatin Pemetrexed	treatment	2	completed
NCT04786964	Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab (CK-301) in First Line Metastatic Non-squamous Non-Small Cell Lung Cancer	Carboplatin Cisplatin Cosibelimab Dexamethasone Pemetrexed	treatment	3	terminated
NCT06028633	Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients	Albumin human Lenvatinib Paclitaxel Pembrolizumab	treatment	2	not_yet_recruiting
NCT06416410	JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation	Carboplatin JAB-21822 Pemetrexed Tislelizumab	treatment	3	recruiting
NCT04205812	Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer	Carboplatin Cisplatin Paclitaxel Pemetrexed Retifanlimab	treatment	3	active_not_recruiting